Huons Global Co Ltd

Chart & Performance

D1W1MN

P/E

13.35

P/S

0.68

EPS

3,133.85

Div Yield, %

3.80%

Shrs. gr., 5y

0.46%

Rev. gr., 5y

14.90%

Revenues

758.38b

+14.15%

Net income

38.38b

CFO

99.97b

+55.29%

Dividend

Jun 27, 2024275 KRW/sh

Profile

Huons Global Co., Ltd. provides medical solutions for human health in South Korea and internationally. The company offers oral solid form products in the areas of circulatory system, metabolic, anti-pyretic analgesic anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, antibiotic, well-being, urogenital system, other chemotherapeutic, and others; and injections in the areas of anesthetic, antipyretic, analgesic, anti-inflammatory, skeletal muscle relaxant, antispasmodic, antihistamine, adrenocortical hormone, enzyme, mineral, solvent, calcium, hemostatic, antidote, antibiotic, metabolic, hyaluronic acid, well-being, anticoagulant, and others, as well as circulatory, respiratory, and other tissue cell systems. It also provides medical devices, eye drop products, and bio products. The company was formerly known as Huons Co., Ltd. and changed its name to Huons Global Co., Ltd. in June 2016. Huons Global Co., Ltd. was founded in 1965 and is headquartered in Seongnam, South Korea.

URL

https://huonsglobal.com/web/home_.php

IPO date

Dec 19, 2006

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	758,379,661 14.15%	664,364,718 15.61%	574,647,695 9.87%
Cost of revenue	572,141,581	512,583,265	440,360,045
Unusual Expense (Income)
NOPBT	186,238,080	151,781,453	134,287,650
NOPBT Margin	24.56%	22.85%	23.37%
Operating Taxes	27,004,572	33,740,386	30,512,909
Tax Rate	14.50%	22.23%	22.72%
NOPAT	159,233,508	118,041,067	103,774,741
Net income	38,383,627 -163.70%	(60,254,135) -1,608.41%	3,994,541 -90.64%
Dividends	(19,480,052)	(5,911,198)	(10,124,898)
Dividend yield	6.72%	2.57%	2.12%
Proceeds from repurchase of equity	531,978	15,348,373	16,126,059
BB yield	-0.18%	-6.66%	-3.37%
Debt
Debt current	176,776,630	217,080,192	180,305,434
Long-term debt	75,468,172	72,473,267	70,144,400
Deferred revenue	9,676,226	9,021,332	10,201,583
Other long-term liabilities	21,673,029	6,420,509	5,362,488
Net debt	(146,369,782)	(201,408,763)	(244,631,940)
Cash flow
Cash from operating activities	99,967,135	64,373,890	49,821,825
CAPEX	(79,774,245)	(78,716,796)	(148,647,532)
Cash from investing activities	(63,464,343)	(1,068,937)	(14,456,129)
Cash from financing activities	(77,309,350)	1,770,588	72,980,059
FCF	(400,341)	69,452,724	32,464,662
Balance
Cash	312,552,775	367,861,473	373,150,053
Long term investments	86,061,809	123,100,748	121,931,721
Excess cash	360,695,601	457,743,985	466,349,389
Stockholders' equity	552,593,118	435,170,878	492,687,457
Invested Capital	828,192,389	636,339,935	623,563,095
ROIC	21.75%	18.74%	17.29%
ROCE	15.60%	14.12%	12.30%
EV
Common stock shares outstanding	12,248	12,289	12,428
Price	23,650.00 26.13%	18,750.00 -51.30%	38,500.00 38.21%
Market cap	289,666,974 25.71%	230,426,438 -51.84%	478,482,812 43.76%
EV	560,221,600	357,818,194	551,845,781
EBITDA	222,218,303	185,355,033	163,537,532
EV/EBITDA	2.52	1.93	3.37
Interest	7,598,050	12,758,610	7,109,107
Interest/NOPBT	4.08%	8.41%	5.29%